Article Figures & Data
Figures
- Figure 1.
Sustained Virologic Response at Week 12 Results: Intention to Treat
GT, genotype; HCV, hepatitis C virus; HIV, human immunodeficiency virus; LTFU, lost to follow-up; RBV, ribavirin; SVR12, sustained viral response at 12 wk post treatment.
aBreakthrough was due to HCV GT-2b (minor GT-2b variant at baseline).
bOne of the patients who relapsed did not receive grazoprevir and only received elbasvir + RBV for the first month of treatment.
Reproduced with permission from MS Sulkowski, MD.
- Figure 2.
Subgroup Analysis of SVR12 Rates (12 Week Arms Only)
CC, having 2 C alleles; GT, genotype; HCV, hepatitis C virus; IL28B, interleukin 28B; SVR12, sustained viral response at 12 wk post treatment.
Reproduced with permission from MS Sulkowski, MD.
Tables
Tools
High Efficacy Rates with Grazoprevir Plus Elbasvir in HCV Monoinfection and HCV/HIV Coinfection
Permalink:
Table of contents
Cited By...
- No citing articles found.